VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX - Free Report) in a research report released on Saturday. The brokerage issued a sell rating on the stock.

Other equities analysts also recently issued reports about the company. Benchmark restated a "hold" rating on shares of VolitionRx in a research report on Friday, November 22nd. D. Boral Capital restated a "buy" rating and issued a $5.00 price target on shares of VolitionRx in a research report on Tuesday.

VolitionRx Price Performance

NYSE VNRX traded down $0.05 during trading hours on Friday, reaching $0.57. The company's stock had a trading volume of 391,483 shares, compared to its average volume of 504,499. The firm has a fifty day simple moving average of $0.68 and a 200-day simple moving average of $0.67. VolitionRx has a 52 week low of $0.43 and a 52 week high of $1.23. The stock has a market cap of $52.36 million, a P/E ratio of -1.57 and a beta of 1.17.

Insiders Place Their Bets

In other VolitionRx news, Director Guy Archibald Innes purchased 174,764 shares of the company's stock in a transaction that occurred on Monday, December 9th. The shares were acquired at an average cost of $0.57 per share, for a total transaction of $99,615.48. Following the completion of the acquisition, the director now owns 617,085 shares of the company's stock, valued at $351,738.45. The trade was a 39.51 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Cameron John Reynolds acquired 139,811 shares of VolitionRx stock in a transaction on Monday, December 9th. The stock was acquired at an average price of $0.57 per share, with a total value of $79,692.27. Following the purchase, the chief executive officer now directly owns 2,117,404 shares in the company, valued at approximately $1,206,920.28. This trade represents a 7.07 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 358,266 shares of company stock worth $204,212. Insiders own 12.80% of the company's stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in VolitionRx stock. Geode Capital Management LLC increased its position in shares of VolitionRx Limited (NYSE:VNRX - Free Report) by 15.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 730,448 shares of the company's stock after acquiring an additional 95,900 shares during the period. Geode Capital Management LLC owned approximately 0.79% of VolitionRx worth $439,000 as of its most recent filing with the Securities and Exchange Commission. 8.09% of the stock is currently owned by hedge funds and other institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.